Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Voyager Therapeutics (VYGR) EBIT (2016 - 2025)

Voyager Therapeutics' EBIT history spans 11 years, with the latest figure at $76.8 million for Q4 2025.

  • For Q4 2025, EBIT rose 300.64% year-over-year to $76.8 million; the TTM value through Dec 2025 reached -$25.1 million, up 69.9%, while the annual FY2025 figure was -$25.1 million, 69.9% up from the prior year.
  • EBIT for Q4 2025 was $76.8 million at Voyager Therapeutics, up from -$30.6 million in the prior quarter.
  • Across five years, EBIT topped out at $122.9 million in Q1 2023 and bottomed at -$39.9 million in Q4 2023.
  • The 5-year median for EBIT is -$24.9 million (2021), against an average of -$10.2 million.
  • The largest annual shift saw EBIT crashed 530.78% in 2022 before it skyrocketed 675.57% in 2023.
  • A 5-year view of EBIT shows it stood at $5.7 million in 2021, then plummeted by 530.78% to -$24.6 million in 2022, then crashed by 62.3% to -$39.9 million in 2023, then rose by 3.93% to -$38.3 million in 2024, then skyrocketed by 300.64% to $76.8 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's EBIT are $76.8 million (Q4 2025), -$30.6 million (Q3 2025), and -$36.6 million (Q2 2025).